Behavior of sartans (antihypertensive drugs) in wastewater treatment plants, their occurrence and risk for the aquatic environment

Environmental Science and Pollution Research

Volumn 21, Issue 18, 2014, Pages 10830-10839

  Bayer, Anne ^a   Asner, Robert ^b   Schüssler, Walter ^b   Kopf, Willi ^b   Weiß, Klaus ^b   Sengl, Manfred ^b   Letzel, Marion ^a  

^a Bavarian Environment Agency   (Germany)

^b Bavarian Environment Agency   (Germany)

Author keywords

Ecotoxicity; Elimination; Mixture toxicity; Monitoring; Pharmaceuticals; Risk assessment

Indexed keywords

ANTHROPOGENIC SOURCE; AQUATIC ENVIRONMENT; BIOMONITORING; DRUG; EFFLUENT; RISK ASSESSMENT; TOXICITY; WASTE TREATMENT; WASTEWATER;

ACRYLIC ACID DERIVATIVE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BIPHENYL DERIVATIVE; CANDESARTAN; EPROSARTAN; IMIDAZOLE DERIVATIVE; IRBESARTAN; OLMESARTAN; TETRAZOLE DERIVATIVE; THIOPHENE DERIVATIVE; VALINE; VALSARTAN; WASTE WATER; WATER POLLUTANT;

ANALOGS AND DERIVATIVES; ANALYSIS; BIOREMEDIATION; CHEMICAL STRUCTURE; CHEMISTRY; ENVIRONMENTAL MONITORING; GERMANY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PROCEDURES; RIVER; SEWAGE; STATISTICS AND NUMERICAL DATA; WASTE WATER; WATER POLLUTANT;

ACRYLATES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIODEGRADATION, ENVIRONMENTAL; BIPHENYL COMPOUNDS; CHROMATOGRAPHY, LIQUID; ENVIRONMENTAL MONITORING; GERMANY; IMIDAZOLES; MASS SPECTROMETRY; MOLECULAR STRUCTURE; RIVERS; TETRAZOLES; THIOPHENES; VALINE; WASTE DISPOSAL, FLUID; WASTE WATER; WATER POLLUTANTS, CHEMICAL;

EID: 84907861175     PISSN: 09441344     EISSN: 16147499     Source Type: Journal    
DOI: 10.1007/s11356-014-3060-z     Document Type: Article

References (46)

1. AUE (2011) Monthly report of the monitoring station at Weil am Rhein. Amt für Umwelt und Energie Basel-Stadt, http://www.aue.bs.ch/2011allweil.pdf (in German)
2. Avdeef A, Barrett DA, Shaw PN, Knaggs RD, Davis SS (1996) Octanol-, chloroform-, and propylene glycol dipelargonat-water partitioning of morphine-6-glucorinide and other related opiates. J Med Chem 39(22):4377–4381
3. Bergmann A, Fohrmann R, Weber F-A (2011) Set of monitoring data of environmental concentrations of pharmaceuticals. Vol 66/2011. Umweltbundesamt (in German)
4. Berkner S, Thierbach C (2013) Biodegradability and transformation of human pharmaceutical active ingredients in environmentally relevant test systems. Environ Sci Pollut Res Int. doi:10.1007/s11356-013-1868-6
5. BUND (2012) www.bund-bawue.de. Accessed 20 Dec 2013 (in German)
6. ChemAxxon http://www.chemicalize.org/. Accessed 5 Jun 2013
7. Cleuvers M (2003) Aquatic ecotoxicity of pharmaceuticals including the assessment of combination effects. Toxicol Lett 142(3):185–194
8. Coetsier CM, Spinelli S, Lin L, Roig B, Touraud E (2009) Discharge of pharmaceutical products (PPs) through a conventional biological sewage treatment plant: MECs vs PECs? Environ Int 35(5):787–792
9. DrugBank http://www.drugbank.ca, DrugBank 3.0. Accessed 5 Jun 2013
10. ECB (2003) Technical guidance document on risk assessment, part II
11. EPA US (2011) EPI Suite™ v4.10. 4.10 edn. United States Environmental Protection Agency, http://www.epa.gov/oppt/exposure/pubs/episuitedl.htm
12. Escher BI, Baumgartner R, Koller M, Treyer K, Lienert J, McArdell CS (2011) Environmental toxicology and risk assessment of pharmaceuticals from hospital wastewater. Water Res 45(1):75–92
13. Fent K, Weston AA, Caminada D (2006) Ecotoxicology of human pharmaceuticals. Aquat Toxicol 76:122–159
14. Ferrer I, Thurman EM (2012) Analysis of 100 pharmaceuticals and their degradates in water samples by liquid chromatography/quadrupole time-of-flight mass spectrometry. J Chromatogr A 1259:148–157
15. Fick J, Lindberg RH, Kaj L, Brorström-Lundén E (2011) Results from the Swedish National Screening Programme 2010; Subreport 3. Pharmaceuticals. Swedish Environmental Research Institute
16. Grubbs FE (1969) Procedures for detecting outlying observations in samples. Technometrics 11(1):1–21
17. Heberer T (2002) Occurrence, fate, and removal of pharmaceutical residues in the aquatic environment: a review of recent research data. Toxicol Lett 131:5–17
18. Helbling DE, Hollender J, Kohler H-PE, Fenner K (2010a) Structure-based interpretation of biotransformation pathways of amide-contaning compounds in sludge-seeded bioreactors. Environ Sci Technol 44:6628–6635
19. Helbling DE, Hollender J, Kohler H-PE, Singer H, Fenner K (2010b) High-troughput identification of microbial transformation products of organic micropollutants. Environ Sci Technol 44:6621–6627
20. Hernando MD, Mezcua M, Fernández-Alba AR, Barceló D (2006) Environmental risk assessment of pharmaceutical residues in wastewater effluents, surface waters and sediments. Talanta 69:334–342
21. Hoeger B (2008) Novartis environmental assessment: Aliskiren / Valsartan. Global Pharma Environment. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022217s000ea.pdf
22. Hollender J, Zimmermann SG, Koepke S, Krauss M, McArdell CS, Ort C, Singer H, von Gunten U, Siegrist H (2009) Elimination of organic micropollutants in a municipal wastewater treatment plant upgraded with a full-scale post-ozonation followed by sand filtration. Environ Sci Technol 43:7862–7869
23. Huber MM, Göbel A, Joss A, Hermann N, Löffler D, McArdell CS, Ried A, Siegrist H, Ternes TA, von Gunten U (2005) Oxidation of pharmaceuticals during ozonation of municipal wastewater effluents: a pilot study. Environ Sci Technol 39:4290–4299
24. Joss A, Keller E, Alder AC, Gobel A, McArdell CS, Ternes T, Siegrist H (2005) Removal of pharmaceuticals and fragrances in biological wastewater treatment. Water Res 39(14):3139–3152
25. Kasprzyk-Hordern B, Dinsdale RM, Guwy AJ (2008) The occurrence of pharmaceuticals, personal care products, endocrine disruptors and illicit drugs in surface water in South Wales, UK. Water Res 42(13):3498–3518
26. Kasprzyk-Hordern B, Dinsdale RM, Guwy AJ (2009) Illicit drugs and pharmaceuticals in the environment—forensic applications of environmental data, part 2: pharmaceuticals as chemical markers of faecal water contamination. Environ Pollut 157(6):1778–1786
27. Kern S, Baumgartner R, Helbling DE, Hollender J, Singer H, Loos MJ, Schwarzenbach RP, Fenner K (2010) A tiered procedure for assessing the formation of biotransformation products of pharmaceuticals and biocides during activated sludge treatment. J Environ Monitor 12:2100–2111
28. Kovalova L, Siegrist H, Singer H, Wittmer A, McArdell CS (2012) Hospital wastewater treatment by membrane bioreactor: performance and efficiency for organic micropollutant elimination. Environ Sci Technol 46:1536–1545
29. Kümmerer K (2008) Pharmaceuticals in the environment: sources, fate, effects and risks, 3rd edn. Springer, Berlin
30. Kümmerer K (2009) The presence of pharmaceuticals in the environment due to human use—present knowledge and future challenges. J Environ Manag 90:2354–2366
31. Kümmerer K (2010) Pharmaceuticals in the environment. Annu Rev Environ Resour 35:57–75
32. Larsson DGJ, de Pedro C, Paxeus N (2007) Effluent from drug manufactures contains extremely high levels of pharmaceuticals. J Hazard Mater 148:751–755
33. Letzel M, Weiss K, Schüssler W, Sengl M (2010) Occurrence and fate of the human pharmaceutical metabolite ritalinic acid in the aquatic system. Chemosphere 81:1416–1422
34. Margot J, Kienle C, Magnet A, Weil M, Rossi L, De Alencastro LF, Abegglen C, Thonney D, Chèvre N, Schärer M, Barry DA (2013) Treatment of micropollutants in municipal wastewater: ozone or powdered activated carbon. Sci Total Environ 461–462:480–498
35. Maycock DS, Watts CD (2011) Pharmaceuticals in drinking water. In: Jerome ON (ed) Encyclopedia of environmental health. Elsevier, Burlington, pp 472–484
36. Miège C, Choubert JM, Ribeiro L, Eusebe M, Coquery M (2009) Fate of pharmaceuticals and personal care products in wastewater treatment plants—conception of a database and first results. Environ Pollut 157(5):1721–1726
37. Mompelat S, Le Bot B, Thomas O (2009) Occurrence and fate of pharmaceutical products and by-products, from resource to drinking water. Environ Int 35:803–814
38. Nikolaou A, Meric S, Fatta D (2007) Occurrence patterns of pharmaceuticals in water and wastewater environments. Anal Bioanal Chem 387:1225–1234
39. Nödler K, Hillebrand O, Idzik K, Strathmann M, Schiperski F, Zirlewagen J, Licha T (2013) Occurrence and fate of the angiotensin II receptor antagonist transformation product valsartan acid in the water cycle—a comparative study with selected β-blockers and the persistent anthropogenic wastewater indicators carbamazepine and acesulfame. Water Res 47(17):6650–6659
40. Scherrer RA, Crooks SL (1989) Titration in water-saturated octanol: a guide to partition coefficients of ion pairs and receptor-site interactions. In: Fauchere JL (ed) Quantitative structure-activity relationships in drug design. New York, pp 59–62
41. Schmitt-Jansen M, Bartels P, Adler N, Altenburger R (2007) Phytotoxicity assessment of diclofenac and its phototransformation products. Anal Bioanal Chem 387:1389–1396
42. Schwabe U, Paffrath D (2010) Report of pharmaceutical prescriptions 2010. Springer, Berlin (in German)
43. Schwabe U, Paffrath D (2013) Report of pharmaceutical prescriptions 2013. Springer, Berlin (in German)
44. Sinclair CJ, Boxall ABA (2003) Assessing the ecotoxicity of pesticide transformation products. Environ Sci Technol 37:4617–4625
45. Statistisches Bundesamt (2012) www.destatis.de. Assessed 20 Dec 2013 (in German)
46. Yu JT, Bouwer EJ, Coelhan M (2006) Occurrence and biodegradability studies of selected pharmaceuticals and personal care products in sewage effluent. Agric Water Manag 86:72–80